What is Retatrutide? A Complete Research Guide to the Triple Agonist Peptide

Retatrutide (GLP-3) has rapidly become one of the most-discussed research peptides in modern metabolic pharmacology. Phase 2 clinical trial data published in 2023 reported dose-dependent body weight reductions exceeding those seen with any previously studied incretin-class compound, generating substantial interest from researchers, clinicians, and informed buyers. For Canadian laboratories working with this compound — and anyone trying to understand what makes it pharmacologically distinct — the answer requires understanding what Retatrutide is, how it works, and where it fits in the broader landscape of metabolic research peptides.

This guide explains what Retatrutide is in comprehensive detail, covering its molecular structure, three-receptor mechanism, clinical development history, research applications, and sourcing considerations for Canadian labs. Our complete Retatrutide research peptide catalog ships at ≥99% HPLC purity with mass-spec-verified identity, batch-specific certificate of analysis, and fast domestic Canadian shipping.

The short version: Retatrutide is an investigational triple receptor agonist peptide developed by Eli Lilly under the code name LY3437943, simultaneously activating the GLP-1, GIP, and glucagon receptors. This three-receptor profile distinguishes it from earlier-generation single-agonist (semaglutide) and dual-agonist (tirzepatide) compounds, producing metabolic effects that no single mechanism can achieve alone. The long version covers the pharmacology, evidence base, and research context in depth.

Table of Contents

• What is Retatrutide? Definition and Overview

• Retatrutide Molecular Structure and Design

• How Does Retatrutide Work? Triple Receptor Agonism Explained

• Retatrutide Clinical Development Timeline

• Retatrutide Phase 2 Clinical Trial Data

• Research Applications of Retatrutide

• How Retatrutide Compares to Other Incretin Peptides

• Sourcing Retatrutide for Canadian Research

• Frequently Asked Questions

What is Retatrutide? Definition and Overview

Retatrutide is an investigational research peptide developed by Eli Lilly under the development code LY3437943, classified pharmacologically as a triple agonist of the GLP-1, GIP, and glucagon receptors. The compound represents the most advanced clinical-stage triple receptor agonist in the metabolic peptide category, currently progressing through Phase 3 development under Eli Lilly's TRIUMPH program.

Several features make Retatrutide pharmacologically distinct from earlier incretin-class compounds:

Triple receptor activity. Where semaglutide activates only the GLP-1 receptor and tirzepatide activates both GLP-1 and GIP receptors, Retatrutide simultaneously engages a third target — the glucagon receptor — adding a metabolic dimension previous incretin compounds couldn't access.

Balanced agonism. Retatrutide's three-receptor activity is engineered to be balanced rather than dominated by any single receptor. This allows research designs to investigate integrated metabolic effects rather than mechanism-isolated activity.

Extended half-life. Structural modifications (Aib substitutions and C20 fatty diacid acylation) extend the compound's circulation time through albumin binding, supporting once-weekly dosing schedules in clinical contexts.

Emerging evidence base. While newer than semaglutide or tirzepatide in clinical development, Retatrutide has accumulated rigorous Phase 2 data and a growing preclinical literature across metabolic, hepatic, and energy-expenditure endpoints.

The compound represents a meaningful pharmacological advancement in the broader category of triple agonist peptide research, opening research applications that single-agonist and dual-agonist compounds cannot directly investigate.

Retatrutide Molecular Structure and Design {#retatrutide-molecular-structure}

Understanding what Retatrutide is at the molecular level requires examining the structural choices that make its three-receptor profile possible.

Retatrutide is a 39-amino-acid peptide engineered through several key structural modifications:

Backbone sequence. The peptide backbone is structurally related to glucagon family hormones, providing the molecular template that engages incretin and glucagon receptors. The specific amino acid sequence was optimized through structure-activity relationship studies to achieve balanced affinity across all three target receptors.

Aib (α-aminoisobutyric acid) substitutions. Two positions in the peptide backbone contain Aib, a non-natural amino acid that protects vulnerable peptide bonds from dipeptidyl peptidase-IV (DPP-4) cleavage. DPP-4 is the enzyme responsible for rapidly degrading endogenous GLP-1 and other incretin hormones — without DPP-4 resistance, peptides in this category would have circulation times measured in minutes rather than hours.

C20 fatty diacid acylation. A 20-carbon fatty diacid is attached to the peptide via a γ-glutamic acid linker, enabling reversible binding to serum albumin. This albumin binding dramatically extends half-life by protecting the peptide from rapid clearance and providing a depot effect — Retatrutide's circulation half-life is approximately 6 days, supporting the once-weekly dosing used in clinical trials.

Balanced receptor affinity. Unlike compounds that strongly favor one receptor over others, Retatrutide was engineered to maintain comparable activity across GLP-1, GIP, and glucagon receptors. This balanced agonism is the central pharmacological innovation distinguishing it from earlier incretin compounds.

These structural features work together to produce a compound that can be administered once weekly, engages three distinct receptor pathways with comparable potency, and resists the rapid degradation that affects natural incretin hormones.

How Does Retatrutide Work? Triple Receptor Agonism Explained {#how-does-retatrutide-work}

Retatrutide's mechanism centers on simultaneously activating three receptors that each contribute different metabolic effects. Understanding this triple agonism is essential to understanding what makes Retatrutide pharmacologically distinct.

GLP-1 Receptor Activation

The GLP-1 receptor is found primarily on pancreatic β-cells, neurons in the hypothalamus and brainstem, and cells throughout the gastrointestinal tract. Retatrutide's GLP-1 receptor activation produces:

• Glucose-dependent insulin secretion from pancreatic β-cells, improving glycemic control without causing hypoglycemia at normal glucose levels

• Glucagon suppression from pancreatic α-cells, reducing hepatic glucose output

• Slowed gastric emptying, blunting postprandial glucose spikes and extending satiety

• Central appetite reduction through hypothalamic and brainstem GLP-1 receptors, decreasing food intake

This component of Retatrutide's activity is the foundation that semaglutide-class drugs operate on. Retatrutide preserves these effects while adding two additional receptor mechanisms.

GIP Receptor Activation

The GIP (glucose-dependent insulinotropic polypeptide) receptor is found on pancreatic β-cells, adipocytes, and central nervous system neurons. Retatrutide's GIP receptor activation contributes:

• Amplified insulin secretion beyond what GLP-1 alone produces

• Adipose tissue modulation affecting fat storage and substrate handling

• Central satiety effects through brain GIP receptors, complementing GLP-1's central effects

• Bone metabolism effects through GIP receptors expressed on bone tissue

GIP agonism was historically considered counterproductive for metabolic therapy, but research with tirzepatide demonstrated that dual GLP-1/GIP activation produces enhanced effects beyond GLP-1 alone. Retatrutide preserves this advantage.

Glucagon Receptor Activation

The glucagon receptor is found primarily on hepatocytes and adipocytes, with smaller populations in the heart and kidneys. Retatrutide's glucagon receptor activation adds:

• Hepatic lipid mobilization, reducing liver fat content through stimulation of hepatic fatty acid oxidation

• Lipolysis in adipose tissue, mobilizing stored triglycerides for energy use

• Increased energy expenditure, raising resting metabolic rate through effects on brown adipose tissue and hepatic substrate cycling

• Hepatic glucose output (the classical glucagon effect that requires offsetting by GLP-1's insulin-stimulating activity)

The glucagon component is what most clearly distinguishes Retatrutide from semaglutide and tirzepatide. The challenge of incorporating glucagon agonism — balancing the glucose-raising effect against the metabolic benefits — was solved through careful tuning of the GLP-1/GIP/glucagon receptor ratio. Sufficient GLP-1 activity offsets glucagon's hepatic glucose output, allowing the other glucagon effects to contribute to net metabolic improvement.

For a deeper explanation of how these three receptor pathways interact, see our companion post GLP-1 vs GIP vs Glucagon Agonism: How Three Receptors Reshaped Metabolic Pharmacology.

Retatrutide Clinical Development Timeline {#retatrutide-clinical-development}

Retatrutide's development timeline provides important context for understanding where the compound sits in the broader pharmaceutical landscape.

2008-2018: Pre-clinical development. Eli Lilly's metabolic peptide research program advanced through dual agonist compounds (eventually producing tirzepatide) and then explored triple receptor combinations. The structural optimization that produced Retatrutide built on lessons learned from earlier incretin compound development.

2020: First clinical disclosure. Eli Lilly first disclosed LY3437943 (Retatrutide) in clinical trial registries and early-phase publications, identifying it as an investigational triple agonist for metabolic indications.

2022: Phase 1 completion. Phase 1 safety and pharmacokinetics studies completed, establishing the dosing parameters used in subsequent Phase 2 trials.

2023: Phase 2 results published. The pivotal Phase 2 trial results were published in The New England Journal of Medicine, reporting dose-dependent body weight reductions of approximately 24% at 48 weeks with the highest dose tested. The publication generated substantial attention from both research and clinical communities.

2023-Present: Phase 3 development. Retatrutide continues development under Eli Lilly's TRIUMPH program — a comprehensive Phase 3 program covering multiple metabolic indications including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Multiple Phase 3 trials are currently enrolling or in progress, with completion expected over the next several years.

Future: If Phase 3 results support the Phase 2 findings, Retatrutide could potentially receive regulatory approval in late 2025 or 2026, positioning it as the first triple agonist incretin-class drug to reach clinical use. As of current publication, the compound remains investigational and available only for research purposes.

Retatrutide Phase 2 Clinical Trial Data {#retatrutide-phase-2-data}

The Phase 2 trial results that brought Retatrutide to broad attention deserve detailed examination for researchers and informed buyers wanting to understand the evidence base.

The Phase 2 obesity trial enrolled 338 participants with body mass index (BMI) of 30 or greater (or 27 or greater with weight-related comorbidities) and tested four Retatrutide doses (1, 4, 8, and 12 mg) administered subcutaneously once weekly for 48 weeks, with placebo as the control group.

Key findings published in The New England Journal of Medicine:

Body weight reduction. At 48 weeks, mean body weight reductions were:

• 1 mg dose: 8.7% reduction

• 4 mg dose: 17.1% reduction

• 8 mg dose: 22.8% reduction

• 12 mg dose: 24.2% reduction

• Placebo: 2.1% reduction

The 24.2% reduction at the highest dose exceeded the approximately 22% maximum seen with tirzepatide in similar duration studies, and substantially exceeded the approximately 15% maximum seen with semaglutide.

Metabolic effects. Beyond weight reduction, the trial documented:

• HbA1c reductions in participants with elevated baseline glucose

• Improvements in cardiometabolic risk markers (blood pressure, lipid profiles)

• Reductions in liver fat content based on imaging-based measurements

• Improvements in physical function measures

Safety profile. Adverse events were consistent with the incretin compound class, primarily gastrointestinal effects (nausea, diarrhea, vomiting) that were dose-dependent and typically diminished over the course of treatment. No new safety signals beyond those seen with other incretin-class compounds were identified.

A separate Phase 2 trial in participants with type 2 diabetes published in The Lancet reported similar magnitude effects on glycemic control and body weight, supporting Retatrutide's activity across multiple metabolic indications.

The Phase 2 data established Retatrutide as the most pharmacologically potent incretin-class compound studied to date, justifying the substantial Phase 3 investment that Eli Lilly is making in the TRIUMPH program.

Research Applications of Retatrutide {#research-applications-retatrutide}

For Canadian laboratories investigating metabolic biology, Retatrutide serves several distinct research applications based on its unique three-receptor pharmacology.

Investigating triple receptor pharmacology

The most distinctive research application is investigating what triple receptor agonism contributes beyond single or dual mechanisms. Research designs commonly use Retatrutide alongside reference compounds:

• Compared against semaglutide as the GLP-1-only reference

• Compared against tirzepatide as the dual GLP-1/GIP reference

• Compared against selective single-receptor agonists for mechanism deconvolution

These comparative designs allow researchers to attribute specific metabolic effects to specific receptor pathways.

Hepatic lipid biology research

The glucagon component of Retatrutide's activity makes it particularly useful for research designs investigating hepatic lipid metabolism — an area that GLP-1-only and dual agonist compounds cannot directly address. Research applications include:

• Non-alcoholic fatty liver disease (NAFLD) model investigation

• Metabolic dysfunction-associated steatohepatitis (MASH) research

• Hepatic fatty acid oxidation pathway research

• Liver-specific metabolic phenotype investigation

Energy expenditure research

Glucagon receptor activation increases resting metabolic rate, providing a research tool for investigating the energy expenditure side of body composition regulation. Research applications include:

• Brown adipose tissue thermogenesis studies

• Mitochondrial uncoupling and metabolic flexibility research

• Resting metabolic rate measurement studies

• Energy balance research designs

Integrated metabolic syndrome research

Because Retatrutide simultaneously affects glucose handling, body weight, lipid profiles, and hepatic function, it serves research designs that need to investigate metabolic syndrome as an integrated phenomenon rather than studying individual components separately.

For comprehensive coverage of compound selection in metabolic research designs, see our Best Peptides for Weight Loss Research comparison guide.

How Retatrutide Compares to Other Incretin Peptides {#retatrutide-comparison}

Understanding what Retatrutide is becomes clearer in comparison to related compounds in the incretin-class category.

The progression from single agonist (semaglutide) to dual agonist (tirzepatide) to triple agonist (Retatrutide) represents a clear pattern of increased pharmacological complexity producing greater metabolic effects. Each additional receptor adds biology that the previous step couldn't reach:

• GLP-1 alone addresses appetite regulation and glucose-dependent insulin secretion

• GLP-1 + GIP adds enhanced insulin amplification, adipose modulation, and central satiety

• GLP-1 + GIP + glucagon adds hepatic lipid mobilization, lipolysis, and energy expenditure

This evolution mirrors how researchers and clinicians have come to understand metabolic disease — as a multi-system phenomenon requiring multi-pathway intervention rather than single-mechanism approaches.

Retatrutide stands at the current frontier of this evolution, with multiple pharmaceutical companies now pursuing additional receptor combinations (amylin, FGF21, GDF15) that may further extend the pattern in coming years.

Sourcing Retatrutide for Canadian Research {#sourcing-retatrutide-canada}

Sourcing Retatrutide as a research compound requires attention to several quality and supply chain factors that affect research reproducibility.

Manufacturing standards. Research-grade Retatrutide should be manufactured under appropriate quality standards with comprehensive analytical verification. Key quality indicators include:

• ≥99% HPLC purity verification on every batch

• Mass spectrometry confirmation of identity

• Batch-specific certificates of analysis

• Documented manufacturing location and quality oversight

Canadian sourcing advantages. For Canadian research labs, domestic Retatrutide sourcing offers several advantages over international suppliers:

• Eliminates customs delays and cross-border supply chain variables

• Maintains cold-chain integrity through shorter shipping distances

• Provides clearer regulatory context under Canadian commercial frameworks

• Enables direct supplier accountability for quality issues

Documentation requirements. For research designs operating under institutional review, peer review, or external audit requirements, Retatrutide sourcing should include:

• Batch-specific COAs traceable to specific manufacturing lots

• HPLC chromatograms documenting purity verification

• MS spectra documenting identity confirmation

• Manufacturer information and quality framework details

Storage and stability. Retatrutide is a modified peptide with fatty acid acylation, which affects storage requirements. Best practices include:

• Refrigerator storage (2-8°C) for short-term use

• Freezer storage (-20°C) for long-term archival

• Light protection and minimal thermal cycling

• Proper handling documentation

For complete coverage of research peptide storage best practices, see our How to Store Research Peptides guide. For comprehensive sourcing considerations across the peptide category, see The Complete Research Peptides Canada Buying Guide for 2026.

Emerald Peptides supplies Retatrutide research peptide at ≥99% HPLC purity with MS-verified identity, batch-specific COAs, and fast domestic Canadian shipping. The compound is sold strictly for research use only.

Frequently Asked Questions {#retatrutide-faq}

What is Retatrutide used for in research?

Retatrutide is used in research designs investigating triple receptor agonism in metabolic biology — specifically the combined effects of GLP-1, GIP, and glucagon receptor activation. Research applications include investigating integrated metabolic regulation, hepatic lipid biology, energy expenditure mechanisms, and metabolic syndrome as a multi-system phenomenon. The compound is sold strictly for laboratory research use only and is not approved for human consumption.

Is Retatrutide the same as Ozempic or Mounjaro?

No. Retatrutide is pharmacologically distinct from both Ozempic (semaglutide) and Mounjaro (tirzepatide), though all three are incretin-class peptides. Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors. Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The triple receptor activity gives Retatrutide a different metabolic profile than the dual or single agonist compounds.

How does Retatrutide compare to Tirzepatide?

Both Retatrutide and tirzepatide are multi-receptor incretin agonists, but Retatrutide adds glucagon receptor activation to the dual GLP-1/GIP activity that tirzepatide provides. In comparable Phase 2 trial duration, Retatrutide produced approximately 24% body weight reduction at maximum dose versus approximately 22% for tirzepatide — a modest but meaningful difference. The additional glucagon receptor activity also opens research applications in hepatic lipid biology and energy expenditure that tirzepatide cannot directly investigate.

What is the difference between Retatrutide and Glucagon?

Glucagon is an endogenous 29-amino-acid hormone that raises blood glucose when blood sugar is low. Retatrutide is a synthetic 39-amino-acid peptide engineered to activate the glucagon receptor as one of three target receptors. The key difference: glucagon alone would raise blood glucose, but Retatrutide's simultaneous GLP-1 activation produces enough insulin secretion to offset glucagon's glucose-raising effect, allowing the metabolic benefits of glucagon receptor activation (lipolysis, energy expenditure, hepatic lipid mobilization) to contribute to net metabolic improvement without compromising glycemic control.

How does Retatrutide work for fat loss?

In research designs, Retatrutide affects body composition through several complementary mechanisms: central appetite reduction through GLP-1 and GIP receptors in the brain, slowed gastric emptying and enhanced satiety, lipolysis in adipose tissue through glucagon receptor activation, hepatic fatty acid oxidation through glucagon receptor activation, and increased resting metabolic rate through glucagon-mediated energy expenditure effects. The combination of reduced energy intake and increased energy expenditure produces the substantial body weight reductions observed in Phase 2 trials.

Where can researchers buy Retatrutide in Canada?

Canadian research labs sourcing Retatrutide should look for suppliers meeting three criteria: ≥99% HPLC purity confirmation on every batch, mass spectrometry verification of identity, and domestic Canadian shipping to eliminate cold-chain interruption variables. Emerald Peptides supplies Retatrutide for research use only, with batch-specific certificates of analysis, MS-verified identity, and fast domestic Canadian shipping. For broader supplier evaluation criteria, see our Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers post.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.